Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Unichem: Restructuring pays off - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Unichem: Restructuring pays off

Sep 21, 2001

The restructuring exercise initiated by Unichem Laboratories seems to be bearing fruit. The company's margins have shown steady improvement in the last two years due to high margin product introductions and increasing focus on exports. The company's domestic formulations business grew by a robust 22.8% last fiscal.

(Rs m) 1QFY01 1QFY02 % change FY01
Sales 647 672 3.8% 2,190
Other Income 5 5 0.9% 27
Expenditure 562 543 -3.3% 1,854
Operating Profit (EBDIT) 85 128 51.3% 337
Operating Profit Margin (%) 13.1% 19.1% 15.4%
Interest (net) 15 15 -3.7% 50
Depreciation 15 17 12.3% 59
Profit before Tax 59 102 71.3% 254
Tax 5 10 108.3% 22
Extraordinary Item -1 -5 -34
Profit after Tax/(Loss) 53 87 63.1% 199
Net profit margin (%) 8.2% 12.9% 9.1%
No. of Shares (eoy) (m) 8.5 8.5 8.5
Diluted Earnings per share* 25.0 40.8 23.4
P/E (at current price) 3.9 6.8
*- annualised

The company now plans to widen its therapeutic reach. Unichem's focus has been on the anti-infectives, enzymes and sedatives, cardiovascular, and central nervous system (CNS) therapeutic segments. Some of its top grossers include the pain treatment drug Ampoxin and digestive disorder medicines - Unienzyme -MPS and Vizylac. The company also has an animal healthcare division, which focuses on antibiotics, reproductive care products, feed supplements and growth promoters.

Last year the company launched two new divisions - Foreva (catering exclusively to women healthcare) and Molecular Generics, which cater to the generics market. The growth drivers were tranquilisers and anti-rheumatics, which registered growth of 18% and 73.4% respectively. While tranquilisers contribute 11.4% to the total turnover, anti-rheumatics contribute around 8.5%. Cardiovascular and CNS also registered healthy growth rates. The growth in the cardiovascular segment was driven by Corvadil-A (hypotensive combinations) and Loprin (anticoagulents). Serta (antidepressant), with a growth rate of 92.9%, was the key growth driver for the CNS category. Cardiovascular and CNS together contribute around 10% to the total turnover.

The company has been launching products in the high margin segments, which has helped it enhance its overall profitability margins. The company introduced eight products last fiscal. Some of the products introduced include Glitase a drug used to treat diabetes, TG-tor a cholesterol reducing drug, Roff-50 a painkiller, Erix Unichem's version of Pfizer's blockbuster drug Viagra and Nutreva a Protein supplement. It plans to introduce 10 products in the current year.

The stock currently trades at Rs 160 discounting its 1QFY02 annualised earnings 4 times. Though the restructuring excerise initiated by the company has paid off, valuations going forward would depend on the success in various new therapeutic segments it plans to venture into.

Equitymaster requests your view! Post a comment on "Unichem: Restructuring pays off". Click here!


More Views on News

UNICHEM LAB Announces Quarterly Results (3QFY19); Net Profit Up 110.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, UNICHEM LAB has posted a net profit of Rs 63 m (up 110.9% YoY). Sales on the other hand came in at Rs 2 bn (up 53.8% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB Announces Quarterly Results (2QFY19); Net Profit Down 61.4% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, UNICHEM LAB has posted a net profit of Rs 177 m (down 61.4% YoY). Sales on the other hand came in at Rs 2 bn (down 42.6% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Are You Ready for the Big Nifty Move in the March Expiry?(Profit Hunter)

Mar 8, 2019

History suggests the Nifty could make a big move in March. Are you prepared to benefit from this opportunity?

Smallcaps Are Rallying and You Need to Make the Most of It Now(Profit Hunter)

Mar 7, 2019

Did you just miss the smallcap rally? Or is there still time to catch up? Read on for answers and more...

The One Sector to Bet on Today as India Grows into a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Mar 7, 2019

India's defence sector is suddenly under the spotlight. Can this sector ride along India's long-term growth story?

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)

Mar 13, 2019

The elements that fueled profit growth for these two companies led to a surge in their stock prices.


Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms


Mar 20, 2019 02:43 PM


  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks